GREENWICH LIFESCIENCES, INC. Remaining Share Repurchase Authorization
GREENWICH LIFESCIENCES, INC. (GLSI) had Remaining Share Repurchase Authorization of $7.54 million as of 2023-12-31, per its 10-K filed 2024-04-15.
Discontinued › Notes › Equity
us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 · last filed 2024-08-14
- 2023-12-31: Stock Repurchase Program, Remaining Authorized Repurchase Amount $7.54M.
- 2023-09-30: Stock Repurchase Program, Remaining Authorized Repurchase Amount $7.54M.
- 2023-06-30: Stock Repurchase Program, Remaining Authorized Repurchase Amount $7.54M.
- 2023-03-31: Stock Repurchase Program, Remaining Authorized Repurchase Amount $7.54M.
| Period end | Stock Repurchase Program, Remaining Authorized Repurchase Amount |
|---|---|
| 2023-12-31 | $7.54M 10-K · filed 2024-04-15 |
| 2023-09-30 | $7.54M 10-Q · filed 2023-10-19 |
| 2023-06-30 | $7.54M 10-Q · filed 2023-08-21 |
| 2023-03-31 | $7.54M 10-Q · filed 2024-08-14 |
| 2022-12-31 | $7.54M 10-K · filed 2023-03-31 |
| 2022-09-30 | $7.54M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $7.54M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $5.51M 10-Q · filed 2023-05-22 |
| 2022-03-15 | $5.51M 10-Q · filed 2022-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |